<DOC>
	<DOCNO>NCT00002875</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high energy x-rays damage tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining radiation therapy chemotherapy may kill tumor cell . It yet know chemotherapy regimen effective combine radiation therapy treat medulloblastoma . PURPOSE : Randomized phase III trial compare two combination chemotherapy treatment plus radiation therapy treat child newly diagnose medulloblastoma .</brief_summary>
	<brief_title>Radiation Therapy Plus Combination Chemotherapy Treating Children With Medulloblastoma</brief_title>
	<detailed_description>OBJECTIVES : I. Assess whether cyclophosphamide-containing combination chemotherapy regimen increase progression-free survival compare lomustine-containing regimen child newly diagnose , average-risk medulloblastoma . II . Determine progression-free overall survival child treat craniospinal radiotherapy local boost radiotherapy total dose 5580 cGy follow adjuvant lomustine/cisplatin/vincristine vs. cyclophosphamide/cisplatin/vincristine . III . Determine long-term neurocognitive , endocrinologic , cardiopulmonary sequela associate craniospinal radiotherapy , local boost radiotherapy , adjuvant chemotherapy child , determine whether replacement lomustine cyclophosphamide alters incidence degree sequela . IV . Determine whether cellular biologic parameter , include tumor molecular genetic analysis , DNA ploidy , mitotic activity marker , immunohistochemical analysis , correlate progression-free survival , overall survival , pattern disease relapse patient . V. Evaluate utility routine magnetic resonance image surveillance study head spine detect subclinical recurrent disease . OUTLINE : This randomize study . Patients stratify participate institution . Following surgery , patient randomize one two group . The first group receive craniospinal irradiation follow boost primary tumor . Beginning within 1 week initiation radiotherapy , patient receive vincristine weekly 8 dos . Beginning 6 week completion radiotherapy , patient receive adjuvant lomustine/vincristine/cisplatin every 6 week total 8 course . The second group receive craniospinal irradiation plus vincristine , follow adjuvant cyclophosphamide/vincristine/cisplatin every 6 week total 8 course . Patients follow every 3 month 1 year , every 6 month 2 year , annually . PROJECTED ACCRUAL : It anticipate 240-300 patient enter 4 year .</detailed_description>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologically confirm posterior fossa medulloblastoma ( CCG diagnosis code 2041 ) Localized disease require , i.e . : No 1.5 square centimeter residual tumor postoperative contrastenhanced CT MRI ( preferably within 72 hour 14 day surgery ) No evidence metastatic disease pre postoperative MRI spine ( dye enhancement ) lumbar cerebrospinal fluid ( CSF ) cytology within 3 day prior surgery Cytologic analysis ventricular CSF allow medical contraindication lumbar puncture approval study chairperson Brain stem involvement eligible PATIENT CHARACTERISTICS : Age : 3 21 diagnosis Performance status : Not specify Hematopoietic : ANC great 1,500/mm3 Platelet count great 100,000/mm3 Hemoglobin great 10 g/dL Hepatic : Bilirubin le 1.5 mg/dL ALT le 1.5 time normal Renal : Nuclear glomerular filtration rate creatinine clearance great 70 mL/min per 1.73 square meter PRIOR CONCURRENT THERAPY : No prior radiotherapy chemotherapy ( corticosteroid ) No 31 day since definitive surgery</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>untreated childhood medulloblastoma</keyword>
</DOC>